Skip to main content
. 2016 Jul 23;7(39):64400–64409. doi: 10.18632/oncotarget.10794

Table 4. Additional treatments in advanced HCC patients with PD after sorafenib (n =141).

Additional treatment n (%)
Sorafenib monotherapy 58 (41)
TACE 24 (17)
HAIC 21(15)
Systemic chemotherapy except for sorafenib 18 (13)
Radiation therapy 18 (13)
Hepatic resection 3 (2)
No treatment 13 (9)

HCC = Hepatocellular carcinoma; PD = progressive disease; TACE = transcatheter arterial chemoembolization; HAIC = hepatic arterial infusion chemotherapy